Stenotrophomonas maltophilia resistant to trimethoprim-sulfamethoxazole: an increasing problem

Ann Clin Microbiol Antimicrob. 2006 Sep 18:5:23. doi: 10.1186/1476-0711-5-23.

Abstract

Stenotrophomonas maltophilia (S. maltophilia) has recently emerged as an important nosocomial pathogen. Treatment of invasive infections caused by this organism is difficult as the bacterium is frequently resistant to a wide range of commonly used antimicrobials. Trimethoprim-sulfamethoxazole (TMP - SXT) is recommended as the agent of choice for the treatment of S. maltophilia infections. However, the development of resistance to this antibiotic represents a real challenge to laboratorians and clinicians. This letter describes the first isolation of S. maltophilia resistant to TMP - SXT from two patients treated at Riyadh Armed Forces Hospital which is a major tertiary hospital in Saudi Arabia.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use*
  • Cross Infection / drug therapy*
  • Drug Resistance, Bacterial
  • Drug Therapy, Combination
  • Fatal Outcome
  • Female
  • Gram-Negative Bacterial Infections / drug therapy*
  • Humans
  • Male
  • Middle Aged
  • Saudi Arabia
  • Shock, Septic / etiology
  • Stenotrophomonas maltophilia / drug effects*
  • Sulfamethoxazole / pharmacology
  • Sulfamethoxazole / therapeutic use
  • Treatment Outcome
  • Trimethoprim / pharmacology
  • Trimethoprim / therapeutic use

Substances

  • Anti-Bacterial Agents
  • Trimethoprim
  • Sulfamethoxazole